Filed with ASX · · 30 pages · English
Epiminder Ltd. has released its operational update for the year to date, along with materials for its Annual General Meeting, highlighting significant progress in its DETECT clinical study for epilepsy treatment. Additionally, Epiminder maintains a strong cash position, which is expected to support its operations and commercialization efforts well into the future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
FY27 YTD operational update and AGM materials YTD FY27 Highlights: ? DETECT reached 75 patient enrolments in September 2026, continuing strong enrolment momentum across leading US epilepsy centres. th ? 100th patient was enrolled in DETECT on 15 October 2026, ahead of the Company’s November...
